Kimura Hirokazu, Shimizu Kaoruko, Tanabe Naoya, Makita Hironi, Taniguchi Natsuko, Kimura Hiroki, Suzuki Masaru, Abe Yuki, Matsumoto-Sasaki Machiko, Oguma Akira, Takimoto-Sato Michiko, Takei Nozomu, Matsumoto Munehiro, Goudarzi Houman, Sato Susumu, Ono Junya, Izuhara Kenji, Hirai Toyohiro, Nishimura Masaharu, Konno Satoshi
Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.
Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.
Ann Allergy Asthma Immunol. 2022 Jun;128(6):682-688.e5. doi: 10.1016/j.anai.2022.03.016. Epub 2022 Mar 24.
The chitinase-like protein YKL-40 is associated with airflow limitation on spirometry and airway remodeling in patients with asthma. It remains unclear whether YKL-40 is associated with morphologic changes in the airways and parenchyma or with future progression of airflow limitation in severe asthma.
To evaluate the association of circulating YKL-40 levels with morphologic changes in the airways and parenchyma and with longitudinal progression of airflow limitation.
The patients were participants in the Hokkaido Severe Asthma Cohort Study (n = 127), including smokers. This study consisted of 2 parts. In analysis 1, we analyzed associations between circulating YKL-40 levels and several asthma-related indices, including computed tomography-derived indices of proximal wall area percentage, the complexity of the airways (airway fractal dimension), and the parenchyma (exponent D) cross-sectionally (n = 97). In analysis 2, we evaluated the impact of circulating YKL-40 levels on forced expiratory volume in 1 second (FEV) decline longitudinally for a 5-year follow-up (n = 103).
Circulating YKL-40 levels were significantly associated with proximal wall area percentage and airway fractal dimension (r = 0.25, P = .01; r = -0.22, P = .04, respectively), but not with exponent D. The mean annual change in FEV was -33.7 (± 23.3) mL/y, and the circulating YKL-40 level was a significant independent factor associated with annual FEV decline (β = -0.24, P = .02), even after controlling for exponent D (β = -0.26, P = .01).
These results provide further evidence for the association of YKL-40 with the pathogenesis of airway remodeling in severe asthma.
几丁质酶样蛋白YKL - 40与哮喘患者肺量计测定的气流受限及气道重塑相关。YKL - 40是否与气道和实质的形态学改变或重度哮喘气流受限的未来进展相关尚不清楚。
评估循环YKL - 40水平与气道和实质形态学改变以及气流受限纵向进展之间的关联。
患者为北海道重度哮喘队列研究的参与者(n = 127),包括吸烟者。本研究由两部分组成。在分析1中,我们横断面分析了循环YKL - 40水平与几个哮喘相关指标之间的关联,包括计算机断层扫描得出的近端壁面积百分比、气道复杂性(气道分形维数)和实质(指数D)(n = 97)。在分析2中,我们纵向评估了循环YKL - 40水平对1秒用力呼气容积(FEV)下降的影响,随访5年(n = 103)。
循环YKL - 40水平与近端壁面积百分比和气道分形维数显著相关(r = 0.25,P = 0.01;r = -0.22,P = 0.04),但与指数D无关。FEV的年平均变化为-33.7(±23.3)mL/年,循环YKL - 40水平是与FEV年度下降相关的显著独立因素(β = -0.24,P = 0.02),即使在控制指数D后(β = -0.26,P = 0.01)。
这些结果为YKL - 40与重度哮喘气道重塑发病机制的关联提供了进一步证据。